NYSE
166.72USD
-1.80 (-1.07%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
9.8B
P/E
—
EPS
—
Beta
0.75
52W range
73.16-184
Day range
165.44–171.54
Open
168.97
Prev close
168.52
Volume
822K
Avg volume
1M
Dividend
0.00
IPO
2015-06-25
https://www.marketbeat.com/instant-alerts/glaukos-q2-earnings-call-highlights-2026-07-29/ · 7/30/2026+1.00
https://www.zacks.com/stock/news/2964014/glaukos-gkos-reports-q2-earnings-what-key-metrics-have-to-say?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|nfm-2964014 · 7/30/2026+1.00
https://www.zacks.com/stock/news/2912346/glaukos-gains-on-q1-earnings-beat-improved-2026-revenue-outlook?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_article-2912346 · 4/30/2026+0.80
https://www.zacks.com/stock/news/2901668/glaukos-wins-permanent-j-code-for-epioxa-keratoconus-therapy · 4/16/2026+1.00
https://www.businesswire.com/news/home/20260217588127/en/Glaukos-Announces-Fourth-Quarter-and-Full-Year-2025-Financial-Results/ · 2/17/2026+1.00
https://www.defenseworld.net/2026/02/08/principal-financial-group-inc-reduces-stock-position-in-glaukos-corporation-gkos.html · 2/8/2026-0.10
https://seekingalpha.com/article/4859476-glaukos-corporation-gkos-presents-at-44th-annual-j-p-morgan-healthcare-conference-transcript · 1/14/2026+0.10
https://www.defenseworld.net/2026/01/04/glaukos-corporation-nysegkos-given-consensus-recommendation-of-moderate-buy-by-brokerages.html · 1/4/2026+0.60
https://seekingalpha.com/article/4841951-glaukos-corporation-gkos-presents-at-ubs-global-healthcare-conference-2025-transcript · 11/11/2025+0.00
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
